Surgical Innovations Group (LSE:SUN) has appointed Alex Warnock, formerly Group Managing Director of SDI Group, as chief executive with effect from 1 October 2026. David Marsh, who has held executive roles at the company for nine years, will step down as CEO and become a non-executive director.

What was announced

On 28 September 2026 AIM-quoted Surgical Innovations Group plc (LSE:SUN), which makes minimally invasive surgical products, announced a change of chief executive that takes effect on 1 October 2026. David Marsh is standing down as CEO and will stay on the board as a non-executive director. Alex Warnock, aged 61, succeeds him.

The company said Mr Marsh will keep supporting the new chief executive, in particular on key relationships and Business development. Neither remuneration arrangements for the incoming CEO nor any change to the non-executive fee structure were disclosed.

The incoming chief executive

Mr Warnock has more than 25 years' experience in senior operational roles in high-technology manufacturing, photonics and regulated medical technology. Most recently he was Group Managing Director of SDI Group plc. Before that he was chief operating officer at Foster & Freeman Ltd, Gooch & Housego plc and Optos plc. According to the company, his expertise includes new product development, bringing complex clinical technologies to market and operational excellence.

The disclosures required under the AIM Rules show that Mr Warnock currently holds no directorships. In the past five years he has been a director of Galton Tradeco Limited, Galton Bidco Limited, Galton Topco Limited, Galton Midco Limited and Foster & Freeman Limited. The announcement does not say whether he holds any shares in the company.

Chairman Roy Davis said that Mr Warnock "has the right skillset to execute on our future plans and deliver long term value to shareholders." Mr Warnock said: "The business has significant potential and a broad range of minimally invasive surgical products with exciting growth opportunities in new markets."

The outgoing chief executive

Mr Marsh came to Surgical Innovations when it acquired Elemental Healthcare, a business he co-founded, and has since held executive roles at the group for nine years. Mr Davis said: "David has played an important role over the last 20 years," and added: "I would like to thank David for his outstanding commitment."

Mr Marsh said he was "pleased to be able to transition from an executive to a Non-Executive role" and that he remains "confident in the opportunities the business has ahead of it."

Moving an outgoing chief executive to a non-executive seat means he keeps his knowledge of the business and its customer relationships on the board. His independence as a non-executive, however, is a matter for the board to judge under the corporate governance code it follows, and the announcement does not address it.

Background

Surgical Innovations designs, manufactures and distributes products for minimally invasive surgery, including port access systems, surgical instruments and retraction devices. The company highlights its "resposable" approach, in which products combine reusable and disposable parts with the aim of cutting clinical waste.

This was a board announcement only and contained no financial information, trading update or change to guidance. It also did not say whether the Leadership change is linked to any review of strategy. Investors wanting to assess the company's current trading and financial position will need to look at its most recent results announcements, which are published separately.

What to watch next

Mr Warnock takes up the role on 1 October 2026. The areas worth watching are any strategic priorities the new chief executive sets out, particularly the "growth opportunities in new markets" he referred to, and the company's next scheduled financial update. The date of that update was not given in the announcement. Any further board changes or share dealings by the new chief executive would be disclosed in separate announcements.